Protagonist Therapeutics, Inc. (PTGX) earnings
PTGX earnings moved a median of +0.11% by the close. Quarterly and annual PTGX reports and results, each read against the price at its own news timestamp. Back to the PTGX overview →
21 measured PTGX earnings events.
Where these PTGX earnings landedvs 21 measured PTGX earnings reactions
| Middle 50% of PTGX earnings reactions | -2.29% to +1.02% |
|---|---|
| Median reaction (to close) | +0.11% |
| Measured reactions | 21 |
Point-in-time · zero look-ahead
Half of the 21 PTGX earnings events with a measured close landed between -2.29% and +1.02%; 57% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Protagonist Therapeutics For: Jun 30 | SEC filing · Form 10-Q | -0.72% | +0.81% | |
| Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -0.72% | +0.81% | |
| Form 10-Q Protagonist Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -1.51% | +0.94% | |
| Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | -1.51% | +0.94% | |
| Form 10-K Protagonist Therapeutics For: Dec 31 | SEC filing · Form 10-K | -0.94% | +1.02% | |
| Form 10-Q Protagonist Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -2.86% | -0.72% | |
| Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -2.86% | -0.72% | |
| Form 10-Q Protagonist Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.15% | -5.84% | |
| Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.15% | -5.84% | |
| Form 10-Q Protagonist Therapeutics For: Mar 31 | SEC filing · Form 10-Q | +0.23% | +3.16% | |
| Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | +0.23% | +3.16% | |
| Form 10-K Protagonist Therapeutics For: Dec 31 | SEC filing · Form 10-K | -2.12% | -7.10% | |
| Form 10-Q Protagonist Therapeutics For: Sep 30 | SEC filing · Form 10-Q | -3.56% | -5.38% | |
| Protagonist Reports Third Quarter 2024 Financial Results and Provides Corporate Update | Press release | -3.56% | -5.38% | |
| Form 10-Q Protagonist Therapeutics For: Jun 30 | SEC filing · Form 10-Q | +1.88% | -2.29% | |
| Protagonist Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.55% | +2.35% | |
| Form 10-Q Protagonist Therapeutics For: Mar 31 | SEC filing · Form 10-Q | -1.96% | +0.11% | |
| Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | -1.96% | +0.11% | |
| Form 10-K Protagonist Therapeutics For: Dec 31 | SEC filing · Form 10-K | +1.28% | +1.43% | |
| Form 10-Q Protagonist Therapeutics For: Sep 30 | SEC filing · Form 10-Q | +0.32% | +5.58% | |
| Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update | Press release | — | +0.00% |
Keep exploring
More PTGX: analyst actions → · SEC filings → · PTGX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Cardinal Health, Inc. (CAH) | 335 | +0.02% | 52% |
| MannKind Corporation (MNKD) | 335 | -0.25% | 43% |
| MYOS RENS TECH INC COMMON (MYOS) | 334 | 0.00% | 43% |
| Actelis Networks, Inc. (ASNS) | 331 | -0.83% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.